UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Aegerion Pharmaceuticals

, and raised its price target from $22.00 to $24.00. Jefferies noted, “At its investor event in New York on 10/23/12, AEGR focused on clinical aspects of lomitapide in HoFH, hosting a panel of 2 lipidologists. There was no commercial agenda. AEGR expects to provide its commercial strategy in early-January 2013 as it is confident of FDA approval of lomitapide by PDUFA date 12/29/12 and EU approval in 1H13. Lomitapide received positive FDA panel votes (13-2 in favor) on 10/17/12.” Aegerion Pharmaceuticals closed on Tuesday at $20.45.